Biotech Markets

Samsung Biologics' all-cash acquisition of PolyPeptide Group — the largest South Korean biopharma deal ever — signals that peptide manufacturing capacity, not discovery, is the binding constraint on the GLP-1 era. Same week, Bachem dropped $615M on a new Swiss facility. The picks-and-shovels play in peptides is accelerating.

For decades, small molecules dominated drug development — elegant chemistry that blocked receptors, inhibited enzymes, and suppressed symptoms. Now a $140 billion peptide therapeutics market is rewriting the playbook. Peptides sit in the Goldilocks zone between small molecules and biologics: specific enough to engage complex protein-protein interactions, small enough to penetrate tissues and cross barriers, and versatile enough to be conjugated to radionuclides, toxins, and drug payloads. The shift from masking disease to solving it at the pathway level may be the most important structural change in pharmaceutical R&D since the introduction of monoclonal antibodies.

On July 1, CMS launched the Medicare GLP-1 Bridge — a time-limited demonstration program covering obesity drugs for the first time in Medicare's history. Several million seniors are eligible. Novo Nordisk and Eli Lilly secured a $245 net price. The fiscal and market implications are enormous — and the clock is ticking.

Biotech VC hit a multi-year high in H1 2026, but the money is going to the same handful of late-stage mega-caps. Early-stage startups are being starved out, and the structural forces driving the gap aren't temporary.

Vertex Pharmaceuticals' $10 billion acquisition of Crinetics adds a launched acromegaly drug and a Phase 3 CAH blockbuster candidate — and signals exactly how the CF giant plans to sustain growth beyond its core franchise. The deal is the fourth $10B+ transaction in a 2026 M&A supercycle already at $134 billion.

Vertex Pharmaceuticals is acquiring Crinetics Pharmaceuticals for $10 billion -- the largest deal in Vertex's history -- gaining an FDA-approved oral acromegaly drug and a Phase 3 congenital adrenal hyperplasia candidate. It's a genuinely de-risked acquisition by biotech M&A standards, and a clear signal Vertex's diversification beyond cystic fibrosis has moved from pipeline bets to M&A.

Biologics now make up roughly half of the industry's active drug pipeline, and semaglutide's FLOW trial kidney data is the strongest proof yet of what they can do that small molecules can't. Here's the capital markets case for the biologics shift -- and where the hype needs a discipline check.

The FDA accepted Sandoz's ANDA filings for generic tirzepatide on June 29, 2026 — the first such challenge against Eli Lilly's Mounjaro/Zepbound franchise. But Lilly's primary compound patent doesn't expire until 2036, meaning this is the opening move in a multi-year Paragraph IV-style patent fight, not a signal that cheap tirzepatide is imminent.

From the first commercial insulin to Humalog to the GLP-1 revolution, Indianapolis has produced century-defining biotech breakthroughs — and generated more than $100 billion in philanthropic capital along the way. The story of Richard DiMarchi, Eli Lilly, and a city that compounded scientific talent across generations.